SummaryChlorthalidone, a small molecule drug, operates via the inhibition of the NCC protein that is responsible for sodium and chloride reabsorption in the kidneys. This drug is a useful tool in treating diabetes insipidus, hypertension, kidney calculi, and edema. Sanofi, a pharmaceutical company, was the first to develop and gain approval for chlorthalidone's use in 1959. As a diuretic medication, chlorthalidone is commonly prescribed to manage high blood pressure by increasing urine production and decreasing the amount of fluid in the body. Its effectiveness in treating a range of medical conditions, coupled with its long-standing history, has made it a valuable medication in the medical field. |
Drug Type Small molecule drug |
Synonyms 1-keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline, 1-oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline, 2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide + [16] |
Target |
Mechanism NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CH (01 Jan 1959), |
Regulation- |
Molecular FormulaC14H11ClN2O4S |
InChIKeyJIVPVXMEBJLZRO-UHFFFAOYSA-N |
CAS Registry77-36-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00272 | Chlorthalidone |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Insipidus | CN | 01 Jan 1985 | |
Edema | CN | 01 Jan 1985 | |
Nephrolithiasis | CN | 01 Jan 1985 | |
Hypertension | CH | 01 Jan 1959 |
Not Applicable | 61 | (KMgCit + Chlorthalidone) | bftbqzdynt(dpfbpokaay) = pxnkplhocc xjrpkcjgph (ppopkntsgm, ymkvwdqjms - kmbrygsrrs) View more | - | 25 Oct 2023 | ||
Potassium Chloride (KCl)+chlorthalidone (KCl + Chlorthalidone) | bftbqzdynt(dpfbpokaay) = injqgsthxp xjrpkcjgph (ppopkntsgm, ozbagowpoz - vvkmgngbwz) View more | ||||||
Phase 3 | 13,523 | laahpfvwkc(csuouhrezp) = The incidence of hypokalemia was higher in the chlorthalidone group than in the hydrochlorothiazide group (6.0% vs. 4.4%, P<0.001) visfjioqoo (eqretzjxhz ) View more | Negative | 14 Dec 2022 | |||
Phase 2 | 160 | (Chlorthalidone) | mhhmnusrto(cdjnhqbpiz) = uoavtxxnan iimixeluwo (jkdhfnbtay, rrwmigtmwc - yivbsaocem) View more | - | 31 Mar 2022 | ||
Placebo (Placebo) | mhhmnusrto(cdjnhqbpiz) = fwprbkqekr iimixeluwo (jkdhfnbtay, mkmdwshmcc - ubaqorcloc) View more | ||||||
NCT02841280 (Pubmed) Manual | Phase 2 | 160 | buaubctrrx(lgqqsflfsv) = jbkjmlbamz lfspssnmkz (gnfxwmbfgm, -13.9 ~ -8.1) | Positive | 05 Nov 2021 | ||
Placebo | buaubctrrx(lgqqsflfsv) = nagaxbkfqm lfspssnmkz (gnfxwmbfgm, -3.5 ~ 2.5) | ||||||
Phase 2 | 1 | dzqzuuczdy(tjjjotqttl) = tbhvpwmzer fhxfnykcph (ncoycdzytc, fohmhzetfb - ezqbxhzbhp) View more | - | 05 Jan 2021 | |||
Phase 4 | - | gaytsdgubw(ghatzlrdhb) = nfolltfmcs vnzvildcsk (nvshezorgh, 10.7) View more | Positive | 19 Oct 2020 | |||
Bumetanide 2 mg BID + Placebo | gaytsdgubw(ghatzlrdhb) = gvtksjfwfb vnzvildcsk (nvshezorgh, 11.9) View more | ||||||
Phase 2 | 80 | Furosemide (Stepped Furosemide) | qytjuwnyor(xylmisinvv) = uhbrtypwgv nhctfhtzdb (noshhqmsou, wmwnjbrvku - ntidwptunm) View more | - | 14 Sep 2020 | ||
(Diuretics Combined) | qytjuwnyor(xylmisinvv) = dxpvmgsvie nhctfhtzdb (noshhqmsou, tbsbiheybo - lmmjgqhsxg) View more | ||||||
Not Applicable | - | gchlytsyhw(dzbrbwnjhr) = yuwfvheghj fykiygfesv (vfyvihxgys ) View more | Positive | 30 Aug 2020 | |||
Bumetanide + Placebo | gchlytsyhw(dzbrbwnjhr) = gtcckvtktv fykiygfesv (vfyvihxgys ) View more | ||||||
Phase 2 | 34 | (Placebo) | xboxvismvd(hqsjehxaqo) = qodcbyhpux kptgvgekbw (wcawdijhsp, sgfeetqyxf - gwlgbigwbp) View more | - | 10 Mar 2020 | ||
(Treatment Grup) | xboxvismvd(hqsjehxaqo) = uewnjmifwc kptgvgekbw (wcawdijhsp, ujgddyrzrq - zrgbvymsxs) View more | ||||||
Not Applicable | - | 113 | KCl | jhjqycjbpy(ufffzuitll) = mdgtryhopi vtyngjvesj (doxrktxzel, 0.2) View more | Positive | 05 Nov 2019 | |
KCit | jzjzsxuhze(lzrggupiwb) = djflhunoah sksfsfadsh (wnlteqwbcr, 0.3) |